Contribute Try STAT+ Today

I told my editor that writing the worst CEOs of biopharma column is one of my most enjoyable work assignments every year. Does that make me a mean, vindictive person? I don’t think so, it’s just fun.

This is a column that needs no introduction. Here are the CEOs who committed blunders or offenses in 2020  egregious enough to land on my naughty list. I have no personal animus against any of these individuals. I hope they all rebound and accomplish spectacular things in 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Why only three on the voting list? I think Nader Pourhassan, CytoDyn should have it by a landslide.

Comments are closed.